梅花生物
(600873)
| 流通市值：314.95亿 | | | 总市值：314.95亿 |
| 流通股本：29.43亿 | | | 总股本：29.43亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 6,486,560,309.24 | 27,760,612,259.07 | 20,526,171,453.75 | 13,588,270,517.23 |
| 营业收入 | 6,486,560,309.24 | 27,760,612,259.07 | 20,526,171,453.75 | 13,588,270,517.23 |
| 二、营业总成本 | 5,754,966,816.91 | 24,158,622,972 | 18,070,945,779.49 | 11,941,801,915.19 |
| 营业成本 | 5,232,609,548.22 | 22,297,122,025.25 | 16,739,334,868.73 | 11,083,605,972.67 |
| 税金及附加 | 54,100,872.32 | 242,593,736.35 | 182,715,154.03 | 118,201,953.51 |
| 销售费用 | 109,209,195.68 | 413,512,921.96 | 306,810,022.38 | 222,525,723.79 |
| 管理费用 | 302,966,862.94 | 924,598,280.87 | 629,017,955.75 | 376,668,549.78 |
| 研发费用 | 90,844,311.14 | 314,222,682.89 | 234,168,723.06 | 149,290,010.79 |
| 财务费用 | -34,763,973.39 | -33,426,675.32 | -21,100,944.46 | -8,490,295.35 |
| 其中:利息费用 | 23,644,161.14 | 115,220,289.9 | 85,716,419.95 | 59,495,510.64 |
| 其中:利息收入 | 34,617,303.5 | 118,865,910.23 | 79,356,020.17 | 47,111,306.88 |
| 加:公允价值变动收益 | 260,000.32 | -38,116,002.85 | -40,168,704.78 | -29,113,667.6 |
| 加:投资收益 | 3,912,130.43 | 7,627,189.35 | -1,153,057.29 | 2,532,420.46 |
| 资产处置收益 | 468,261.36 | 4,073,026.92 | 2,481,311.21 | 2,456,981.19 |
| 资产减值损失(新) | - | -5,415,349.06 | -918,528.02 | -1,409,550.67 |
| 信用减值损失(新) | - | -5,225,785.54 | -6,877,434.93 | -7,415,485.96 |
| 其他收益 | 149,619,138.69 | 248,461,028.47 | 176,521,208.23 | 43,546,575.54 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 885,853,023.13 | 3,813,393,394.36 | 2,585,110,468.68 | 1,657,065,875 |
| 加:营业外收入 | 839,433.54 | 10,357,039.99 | 6,238,092.4 | 3,878,667.01 |
| 减:营业外支出 | 11,161,236.8 | 100,614,814.2 | 56,731,357.04 | 47,456,761.33 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 875,531,219.87 | 3,723,135,620.15 | 2,534,617,204.04 | 1,613,487,780.68 |
| 减:所得税费用 | 123,826,654.08 | 542,185,924.67 | 374,103,252.97 | 242,643,815.8 |
| 六、净利润 | 751,704,565.79 | 3,180,949,695.48 | 2,160,513,951.07 | 1,370,843,964.88 |
| 持续经营净利润 | 751,704,565.79 | 3,180,949,695.48 | 2,160,513,951.07 | 1,370,843,964.88 |
| 归属于母公司股东的净利润 | 751,704,565.79 | 3,180,949,695.48 | 2,160,513,951.07 | 1,370,843,964.88 |
| (一)基本每股收益 | 0.26 | 1.06 | 0.72 | 0.45 |
| (二)稀释每股收益 | 0.26 | 1.06 | 0.72 | 0.45 |
| 八、其他综合收益 | 10,898,041.98 | -535,384,994.54 | 287,459,668.83 | 919,739,712.58 |
| 归属于母公司股东的其他综合收益 | 10,898,041.98 | -535,384,994.54 | 287,459,668.83 | 919,739,712.58 |
| 九、综合收益总额 | 762,602,607.77 | 2,645,564,700.94 | 2,447,973,619.9 | 2,290,583,677.46 |
| 归属于母公司股东的综合收益总额 | 762,602,607.77 | 2,645,564,700.94 | 2,447,973,619.9 | 2,290,583,677.46 |
| 公告日期 | 2024-04-09 | 2024-03-19 | 2023-10-19 | 2023-08-19 |
| 审计意见(境内) | | 标准无保留意见 | | |